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Abstract
Background: Respiratory syncytial virus (RSV) causes severe bronchiolitis and is a risk factor for
asthma. Since there is no commercially available vaccine against RSV, a short interfering RNA
against the RSV-NS1gene (siNS1) was developed and its potential for decreasing RSV infection and
infection-associated inflammation in rats was tested.
Methods: Plasmids encoding siNS1 or an unrelated siRNA were complexed with a chitosan
nanoparticle delivery agent and administered intranasally. Control animals received a plasmid for a
non-specific siRNA. After expression of the plasmid in lung cells for 24 hours, the rats were
intranasally infected with RSV.
Results: Prophylaxis with siNS1 significantly reduced lung RSV titers and airway hyperreactivity to
methacholine challenge compared to the control group. Lung sections from siNS1-treated rats
showed a sizable reduction in goblet cell hyperplasia and in lung infiltration by inflammatory cells,
both characteristics of asthma. Also, bronchoalveolar lavage samples from siNS1-treated animals
had fewer eosinophils. Treatment of rats with siNS1 prior to RSV exposure was effective in
reducing virus titers in the lung and in preventing the inflammation and airway hyperresponsiveness
associated with the infection that has been linked to development of asthma.
Conclusion: The use of siNS1 prophylaxis may be an effective method for preventing RSV
bronchiolitis and potentially reducing the later development of asthma associated with severe
respiratory infections.
Background
Respiratory syncytial virus (RSV) is the predominant cause
of severe bronchiolitis and pneumonia in infants world-
wide and also results in lower respiratory tract infections
in immunodeficient and elderly adults [1]. Children born
prematurely or with congenital heart abnormalities are at
especially high risk for life-threatening respiratory infec-
tions by viruses such as RSV. Severe lower respiratory tract
infection in infants can be fatal and frequently leads to
costly hospital stays. RSV bronchiolitis in infancy is also a
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predisposing factor for the development of asthma later in
life [2]. There is no effective vaccine commercially availa-
ble against RSV and the relative weakness of the immune
response in the target populations of infants and the eld-
erly renders this possibility even less likely.
One of the most promising current strategies for protec-
tion against respiratory tract infection is intranasal treat-
ment with vectors capable of generating RNAs that block
viral replication. RNA interference (RNAi) is a natural
defense of the innate immune system against viruses [3].
Double-stranded viral RNA produced during viral replica-
tion is recognized by the host RNAi system which cleaves
it into short oligoribonucleotides, 20–30 bases long.
These short interfering RNAs (siRNAs) then activate the
cell's RNA cleavage machinery (the RNA interference
silencing complex, or RISC) to destroy the viral RNA. The
RSV genome is a single-stranded, negative-strand RNA
that is copied by a viral RNA-dependent RNA polymerase
into many positive-strand (sense) messages that are then
translated into viral proteins. By introducing siRNAs com-
plementary to specific viral mRNAs, double-stranded acti-
vating RNA can be generated that turns on the RISC
cleavage system and destroys the viral message. This anti-
viral strategy has been tested successfully in cell culture
and animal models against a number of human patho-
gens including influenza [4,5], hepatitis A and C [6,7],
West Nile virus [8] and HIV [9,10]. The field of antiviral
siRNA has recently been reviewed by Manjunath et al.
[11].
We and others have demonstrated the effectiveness of
antiviral siRNA using a BALB/c mouse model for RSV
[12,13] and dengue virus infection [14]. The RSV genome
encodes 10 proteins, and the first two genes transcribed
generate nonstructural proteins known as NS1 and NS2
which are not part of the viral capsid. RSV has evolved a
mechanism to counteract the body's interferon-inducible
antivirus program and this was shown to involve NS1 and
NS2 [15].
The NS1 mRNA is the first message produced during viral
transcription and was chosen as the target for siRNA
because it is known to inhibit the host antiviral defense
system by reducing synthesis of type one interferons, IFN-
α and IFN-β [16]. Loss of interferon production prevents
activation of 2'–5' oligoadenylate synthase, the inducer of
RNase L which degrades viral RNAs. Other antiviral
enzymes blocked by NS1's inhibition of IFN-α, -β include
the double-stranded RNA-dependent protein kinase and
indoleamine 2,3-dioxygenase which normally reduce
virus production by interfering with translation [12].
Deletion mutants of human RSV lacking NS1 or NS2
showed about 10-fold attenuated replication in Vero cells,
but when intranasally inoculated into cotton rats, the
NS1- or NS2-defective virus was reduced 100-fold relative
to wild type [17]. A recombinant RSV deficient in NS1 was
also only poorly infective in chimpanzees [18]. This sug-
gested that the NS proteins of RSV, especially NS1, are crit-
ical for the in vivo replication of the virus and that RNA
interference targeting these proteins should result in a sig-
nificant reduction in RSV infectivity.
An integral part of siRNA therapy is the method of deliv-
ery of the interfering RNA. While naked RNA has been
effectively used to turn off specific gene expression, it is
thought that an RNA expression vector system may pro-
duce a more stable and long-lasting inhibition. Our lab
has developed a plasmid-delivery system utilizing bio-
compatible nanoparticles made from the deacetylated
glucosamine polymer, chitosan, a derivative of naturally
occurring chitin from crustacean shells. Chitosan has been
used for drug delivery and DNA complexation for a
number of years [19] and has been proven safe for human
use [20]. Expression plasmids for a desired gene product
or siRNA can be adsorbed to the nanoparticles through
interaction with the positively charged amine groups on
chitosan, and the complex can be instilled intranasally
into mice or other animals [21,22]. Chitosan has mucoad-
hesive properties that serve to target intranasally adminis-
tered chitosan-plasmid nanoparticles to the lung mucosa
where they may be taken up and expressed in macro-
phages and epithelial cells [23]. Protein expression from
nanoparticle complexes has been found to persist in vivo
for 2 to 3 weeks, and mice treated with a chitosan-inter-
feron gamma plasmid complex were resistant to repeated
RSV infections [unpublished results].
Here we report on the prophylactic effects of an siNS1
construct in preventing RSV infection in rats. Plasmids
expressing anti-NS1 RNA or an unrelated sequence were
complexed with chitosan nanoparticles and instilled
intranasally one day prior to intranasal infection with
RSV. The siNS1 treatment reduced RSV titers significantly
and prevented the accompanying lung damage and airway
hyperreactivity.
Materials and methods
Animals
Fischer 344 rats (14 weeks old) were purchased from Jack-
son Laboratory (Bar Harbor, ME) and maintained in a
pathogen-free environment. All procedure were reviewed
and approved by the University of Miami Committee on
Animal Research.
Cell lines and virus production
The HEp-2 cell line and RSV-A2 strain VR-1302 were
obtained from the American Type Culture Collection
(ATCC, Rockville, MD). The cell line was grown in Earle'sGenetic Vaccines and Therapy 2007, 5:4 http://www.gvt-journal.com/content/5/1/4
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modified Eagle's medium (EMEM), supplemented with
10% fetal bovine serum at 37°C in 5% CO2/95% air. For
RSV production, HEp-2 cells at 60% confluence were
infected with RSV at a multiplicity of infection (MOI) of
0.1 to 0.2 in OptiMEM (Invitrogen, Carlsbad, Calif.) for 2
h at 37°C. The medium was replaced with OptiMEM plus
2% FBS and the infection was allowed to progress until
cytopathological effects were evident by microscopic
examination. Cells were collected by scraping and centri-
fuged at 2100 × g for 10 min at 4°C. Supernatants were
mixed with one-tenth volume of 1 M MgSO4, layered onto
30% glycerol in 50 mM HEPES (pH 7.5) and centrifuged
in an SW 28 rotor at 24,000 × g for 3 h at 4°C. The viral
pellet was gently rinsed with OptiMEM, resuspended at
4°C in 750 µl of 50 mM HEPES (pH 7.5), 0.01 M MgSO4
and 150 mM NaCl (filtered though 0.22 µm pore filter),
aliquotted, and stored in liquid nitrogen.
Construction of siRNA plasmids
The Ambion siRNA Target Finder and Design Tool was
used to find potential siRNA targets along the NS1
sequence and the most effective one by in vitro transcrip-
tion analysis was selected for use in the experiments
reported here. An oligonucleotide was synthesized con-
taining a 24 nt sequence of RSV NS1 (GGCAGCAAT-
TCATTGAGTATGCTT) followed by an 8 nt loop sequence
and the reverse complement of the NS1 target sequence.
The nucleotide sequence for this oligo is 5'-GGC AGC AAT
TCA TTG AGT ATG CTT CTC GAA ATA AGC ATA CTC AAT
GAA TTG CTG CCT TTT TG-3'. When transcribed, the
transcript forms a stem-loop structure. A second oligo was
synthesized complementary to the first with restriction
enzyme sites for Apa-1 and Eco-R1 at the 5' and 3' ends,
respectively. The oligos were annealed and ligated into the
siRNA expression vector, pSilencer 1.0-U6 (Ambion) to
generate the construct, pSMWZ-1. The exact size of the
siNS1 after Dicer processing was not determined. For the
unrelated construct, siE7 (siRNA against the E7 protein of
human papilloma virus, HPV18) the sequence is 5'-GAA
AAC GAT GAA ATA GAT GTT CAA GAG ACA TCT ATT
TCA TCG TTT TCT TTT TT-3'. To determine the possibility
of off-target interactions, a BLAST search of mouse and
human databases was done using the siRNA sequences
and no significant homologies were found. Immunoblots
using antibody specific for NS1 were done on protein iso-
lates from transfected cells to verify knockdown of NS1 by
the siRNA construct.
Preparation of chitosan nanocomplexes and treatment 
with siRNA and RSV
Plasmids were complexed with chitosan nanoparticles as
previously described to enhance stability and targeting of
DNA to lung epithelial cells [21]. Plasmids were dissolved
in 25 mM sodium sulfate and heated at 55°C for 10 min.
High MW chitosan (Protasan CL113, Novamatrix, Nor-
way) was dissolved in 25 mM sodium acetate (pH 5.5) at
a concentration of 0.02% and heated at 55°C for 10 min.
The plasmid solution was then mixed with an equal
amount of chitosan solution (5:1, weight to weight ratio
of chitosan to DNA) and vortexed at high speed for 30 sec.
Fischer 344 rats (14 weeks old; n = 6 in each group) were
given a single intranasal dose of 200 µg of siNS1 or con-
trol plasmid complexed with an equal amount of chi-
tosan. After 24 h, they were intranasally inoculated with
1.4 × 107 PFU of RSV and the infection was allowed to
continue for 5 days at which time the animals were euth-
anized. RSV titers were measured in lung homogenates.
Measurement of airway hyperreactivity (AHR)
On day 4 of RSV infection, the AHR in response to meth-
acholine challenge was measured by unrestrained, whole-
body plethysmography (Buxco Instrument Co., Wilming-
ton NC). Rats were placed inside Plexiglas chambers and
their breathing rate and volume was monitored by pres-
sure-sensitive tranducers inputting the amplified signals
into proprietary software that had been calibrated for the
experimental conditions (Buxco). After an acclimation
period of about 5 min, the baseline enhanced pause
(Penh), a measure of airway resistance, was determined by
exposing the animals to an aerosol of saline and calculat-
ing Penh according to an algorithm developed by Buxco.
Methacholine at specifically metered dose rates was then
fed into the chambers and the Penh measured. The final
Penh value for each rat is the average of all readings taken
over a 5 minute period, and is expressed as percentage of
baseline. An average of the Penh for all animals was used
to compare the response of controls to siNS1-treated rats.
RSV titer in the lung
At the end of the 5-day RSV infection period, rats were
euthanized, lungs were removed and homogenized at
4°C using a Polytron (Brinkmann, Westbury, NY). Lung
homogenates were centrifuged and equal amounts (based
on the weight of lung homogenized) of supernatants were
diluted 1:4 into EMEM culture medium. The homoge-
nates were added to HEp-2 cells (80% confluent) and
incubated at 37°C, with rocking every 15 min. After 2 h,
the medium was replaced with fresh EMEM plus 10% FBS
and cells were incubated for a further 16 h. The viral titer
was measured by immunofluorescence using a FITC-con-
jugated antibody to RSV (Chemicon, Temecula, CA). Eth-
anol-fixed cells were stained for 30 min at 37°C and RSV-
infected cells were counted by fluorescence microscopy.
Bronchoalveolar lavage (BAL) cell differential
At the end of the 5-day infection period, the rats were
euthanized and lungs were lavaged intratracheally with
two washes of phosphate-buffered saline (PBS). The
recovered BAL fluid was centrifuged at 700 × g for 5 min
at 4°C and the cell pellet was resuspended in 200 µl ofGenetic Vaccines and Therapy 2007, 5:4 http://www.gvt-journal.com/content/5/1/4
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PBS. The BAL supernatants were used for cytokine analysis
by ELISA (see below). The cell suspensions were then cen-
trifuged onto glass slides using a Cytospin centrifuge
(Shandon Instrument Co., Pittsburgh, PA) at 1000 × g for
5 min at room temperature. Aliquots of each BAL fluid
sample were applied to three slides. The slides were air
dried and cells were stained with a modified Wright's stain
(Leukostat, Fisher Scientific, Atlanta, GA) which allows
differential counting of monocytes and lymphocytes. A
minimum of 300 cells per sample were counted by direct
microscopic observation.
IFN-γ and IL-4 analysis
IFN-γ and IL-4 levels were measured in BAL fluid superna-
tants and in rat lung homogenates (for sample preparation,
see above) using ELISA kits according to the manufacturer's
instructions (Rat Quantikine Colorimetric Sandwich
ELISA Kits, R & D Systems, Minneapolis, MN).
Staining of lung sections for CD4 and CD8 lymphocytes
Lung sections from siNS1-treated and control rats were
fixed in 4% buffered paraformaldehyde then stained with
PE-labeled anti-CD4 and FITC-labeled anti-CD8. Sections
were examined by fluorescence microscopy and photo-
graphed.
Statistical analysis
Values for experimental data are the average of at least two
and usually three experiments and are expressed as means
± SEM (standard error of the mean). Comparisons were
done using Student's t test and differences with p < 0.05
were considered significant.
Results
siNS1 reduces RSV infection and pulmonary pathology
Rats were given prophylactic anti-RSV treatments consist-
ing of chitosan nanoparticles complexed with siNS1 plas-
mid or an unrelated plasmid instilled intranasally.
Plasmid expression was allowed to proceed for 24 hours
at which time the rats were infected with RSV.
Animals were sacrificed five days after infection and lung
sections were examined microscopically for signs of RSV-
induced lung pathology. SiNS1-treated rats showed less
goblet cell hyperplasia in the bronchioles (upper photos)
and fewer infiltrating inflammatory cells in the interstitial
regions (lower photos) compared to controls. (Fig. 1A).
The number of RSV plaque-forming units in lung
homogenates was also significantly decreased in rats
treated with siNS1 (Fig. 1B).
siNS1 prevents RSV-induced lung pathology and reduces virus titer in the lung Figure 1
siNS1 prevents RSV-induced lung pathology and reduces virus titer in the lung. Rats were given intranasal treat-
ments with chitosan-vector nanocomplexes of siNS1 or unrelated siRNA (control) followed 24 h later by intranasal inoculation 
with RSV. Five days later, the rats (n = 4) were sacrificed and lungs were removed, sectioned and stained for microscopic 
examination. The experiment was repeated once and a representative photomicrograph is shown (A). Another group of rats 
(n = 6) treated in the same way was used to determine RSV levels in the lung. Homogenates of lung tissue were assayed for 
RSV titer by immunofluorescence (B, *p < 0.05).
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siNS1 enhances IFN-γ expression but not IL-4
Bronchoalveolar lavages were done on rats treated with
nanoparticles carrying siNS1 or control plasmid, and IFN-
γ and IL-4 were measured in BAL fluid supernatants by
ELISA. The data showed that IFN-γ was significantly
increased (p < 0.05) in siNS1-treated rat lungs (Fig. 2A)
but there was no significant change in IL-4 levels between
the siNS1 group and controls (Fig. 2B).
siNS1 shifts the T lymphocyte population from Th2 to Th1
The ratio of IL-4 to IFN-γ is an indicator of the allergic phe-
notype in the lung–the higher the ratio, the more T helper
2-like (Th2) is the response [24]. In Fig. 2C, it can be seen
that expression of siNS1 leads to a lower IL-4:IFN-γ ratio;
thus a more Th1-like response to RSV infection was seen
in those rats receiving treatment. In agreement with the
switch from a Th2 to a Th1 phenotype, we found that
siNS1 treatment substantially reduced the number of lung
eosinophils (Fig. 2D). The shift from a Th2 to a Th1 type
response resulting from siNS1 treatment reduces RSV-
induced eosinophilia, presumably by inhibiting expres-
sion in the lung of chemokines such as eotaxin and IL-8
that attract leukocytes [25].
Rat lung airway reactivity is decreased by siNS1
The effect of siNS1 treatment on airway hyperreactivity
(AHR) to methacholine was measured as change in the
enhanced pause (Penh) relative to baseline by whole-
body plethysmography. siNS1-treated rats showed signif-
icantly lower AHR (% Penh) compared to controls (Fig.
3).
T lymphocyte infiltration in lung is altered by siNS1 
treatment
RSV infection typically results in a migration of CD4+ T
cells to the lung and interstitial infiltration of the sur-
siNS1 promotes IFN-γ production in the lung and reduces eosinophilia Figure 2
siNS1 promotes IFN-γ production in the lung and reduces eosinophilia. Rats (n = 6) were treated with siNS1 or con-
trol vector, then 24 h later intranasally infected with RSV. Five days later bronchoalveolar lavage was done and levels of IFN-γ 
and IL-4 measured in the BAL supernatants (A-C). BAL cells were counted and the percentage of eosinophils (ephils) and lym-
phocytes (lyms) was determined by differential staining (D). Experiments were repeated twice and values are means ± SEM (*p 
< 0.05).
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rounding tissues. Intranasal administration of siNS1
reduced the number of CD4+ T cells in the lung but did
not significantly alter the infiltration of CD8+ cells (Fig.
4). The CD4+ T cell infiltration associated with RSV infec-
tion can promote clearance of the virus but at the expense
of increased damage to lung epithelium and parenchyma.
The decrease in CD4+ T cell numbers in the lung pro-
duced by siNS1 treatment when combined with enhanced
interferon antiviral activity generates a highly effective
viral clearance without damaging airway tissues.
Discussion
RSV is a ubiquitous virus of worldwide distribution, and
RSV infection is a serious health risk for bronchiolitis and
pneumonia among children less than six months old. It is
one of the major causes of hospitalization in that age
group. The difficulty of producing an effective vaccine
against RSV in infants arises from the immaturity of their
immune system which is at a stage of development that
precludes a full-scale immune response. Therefore, effec-
tive antiviral prophylaxis in infants must utilize a different
approach. RNA interference to knock down key viral genes
necessary for replication is a promising strategy for achiev-
ing such a reduction in the incidence or severity of RSV
infection. In our rodent experiments, prophylactic treat-
ment as early as three days prior to RSV infection still
afforded some protection against the virus. Therapeutic
siNS1 applications may also be effective in attenuating an
existing RSV infection by blocking additional virus repli-
cation.
The immune response to viral infection involves specific
lymphocyte proliferation and differentiation changes
defined by the T helper cell phenotypes Th1 or Th2 and
their associated cytokine expression. RSV infection is com-
monly associated with a Th1/Th2 imbalance that is
shifted towards the Th2 phenotype characterized by lower
IFN-γ production and increased IL-4. IFN-α is known to
promote a Th1-type response [26] and the inhibition of
IFN-α by the NS1 protein may be associated with this Th2
polarization. Blocking NS1 synthesis shifts the balance
back to a Th1 phenotype and prevents the RSV-induced
blunting of the host's immune response by enhancing
IFN-γ production and thereby potentially allowing full
expression of antiviral interferons and the 2',5'-oligoade-
nylate synthase and RNase L defense systems.
The association between CD4+ T cell infiltration and lung
pathology during RSV infection has been documented
[27]. Passive introduction of CD4+ T cells isolated from
RSV-infected mice into naïve mice followed by intranasal
administration of RSV led to severe lung damage and eosi-
nophilia [28]. The observation that blocking the expres-
sion of the RSV NS1 protein decreased CD4+ T cell levels
in the lung is an important finding that suggests NS1 may
have effects on the adaptive immune system in addition
to its role in subverting the innate interferon response.
The interaction between regulatory T cells and effector T
cells in the immune response to RSV infection may be
another area of involvement of the NS proteins [29].
Conclusion
RNA interference is being aggressively tested as a new and
effective way of specifically silencing genes involved in
disease pathogenesis. Currently there are three clinical tri-
als underway to test the safety and efficacy of siRNAs–two
for macular degeneration and one against RSV-induced
pneumonitis. The RNA interference technique has virtu-
ally unlimited potential but its successful application will
depend largely on the continued elucidation of the pro-
tein interactions and signaling pathways involved in the
etiology of complex diseases such as cancer and asthma.
The use of siRNA as an antiviral agent involves a relatively
straightforward attack on one or more key viral genes and
should be effective against many human pathogens
including influenza and HIV as well as RSV. The use of
non-integrating plasmid vectors obviates the risk of posi-
tional mutagenesis caused by some viral vectors, and the
development of specific drug-delivery systems such as our
chitosan-based nanoparticles can provide efficient target-
ing to infected cells. In this report, the effectiveness of
RNA interference in reducing RSV infection and lung
pathology was demonstrated in an animal model. It is
hoped that this strategy can be implemented to stop the
worldwide morbidity and mortality associated with RSV
infection in infants and immunodeficient adults where
vaccination is ineffective.
siNS1 prevents RSV-induced airway hyperresponsiveness Figure 3
siNS1 prevents RSV-induced airway hyperrespon-
siveness. Rats (n = 4) were treated with siNS1 or control 
vector followed by RSV 24 h later. AHR in response to 
methacholine was measured 5 days later by whole-body 
plethysmography and the enhanced pause (Penh) was 
expressed as percentage of baseline (buffer only). Experi-
ments were repeated twice. *p < 0.05, **p < 0.01.
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siNS1 decreases CD4+ T cell infiltration of lung tissue Figure 4
siNS1 decreases CD4+ T cell infiltration of lung tissue. Rats (n = 6) were given siNS1 or control vector followed by 
RSV 24 h later. After 5 days, the lungs were removed, sectioned and stained for CD4 and CD8. Experiments were repeated 
twice and representative fluorescent micrographs are shown.
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